NASDAQ:KTTA Pasithea Therapeutics Q3 2026 Earnings Results & Report $0.43 -0.07 (-13.14%) Closing price 04:00 PM EasternExtended Trading$0.43 0.00 (-0.07%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pasithea Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.20 versus the -$0.21 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Pasithea Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS -$0.21Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersPasithea Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$200 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Pasithea Therapeutics Q3 2026 Earnings FAQ Did Pasithea Therapeutics beat earnings estimates for Q3 2026? Pasithea Therapeutics (NASDAQ:KTTA) reported earnings of -$0.20 per share for Q3 2026, beating the consensus estimate of -$0.21. The report was announced on Friday, November 13, 2026. Pasithea Therapeutics Earnings HeadlinesPasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock UpNovember 13, 2026 | rttnews.comPasithea oral drug shrank NF1 skin tumors in all 15 evaluable patients; no placebo groupNovember 13, 2026 | msn.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 17 at 1:00 AM | Weiss Ratings (Ad)Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform ...November 13, 2026 | finance.yahoo.comPasithea Therapeutics Reports Positive PAS-004 Clinical Data in NF1-Associated Neurofibromas and FDA Clearance for Phase 2 cNF TrialNovember 13, 2026 | quiverquant.comQPasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis ConferenceNovember 13, 2026 | globenewswire.comSee More Pasithea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email. Email Address About Pasithea TherapeuticsPasithea Therapeutics (NASDAQ:KTTA) is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options. Pasithea is headquartered in the United States and is listed on the Nasdaq under the ticker KTTA.View Pasithea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.